AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference

   AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare                                   Conference  PR Newswire  REDWOOD CITY, Calif., April 4, 2014  REDWOOD CITY, Calif., April 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, and Timothy E. Morris, CFO, will present a Company update on April 9^th. Presentation details are as follows:  13^th Annual Needham Healthcare Conference Date: Wednesday, April 9, 2014 Location: The Westin NY Grand Central Hotel, NY Presentation Time: 10:40 am ET, 7:40 am PT  This presentation will be webcast live and can be accessed through the Investors page at www.acelrx.com. For those not available to listen to the live broadcast, a replay of this presentation will be archived for 90 days and available through the Investors page on www.acelrx.com.  About AcelRx Pharmaceuticals, Inc.  AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx's lead product candidate, Zalviso™, is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed patient-controlled analgesia device.AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, and has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting. AcelRx plans to initiate a Phase 3 clinical trial for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting, during the second half of 2014.The company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development.For additional information about AcelRx's clinical programs, please visit www.acelrx.com  Forward-Looking Statements  This press release contains forward-looking statements, including, but not limited to, statements related to submission of the NDA for Zalviso, planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including planned Phase 3 clinical trial for ARX-04, and the therapeutic potential of Zalviso and other AcelRx Pharmaceuticals' product candidates. These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: AcelRx's ability to receive regulatory approval for Zalviso; any delays or inability to obtain and maintain regulatory approval of its product candidates, including Zalviso, inthe United StatesandEurope; the success, cost and timing of AcelRx Pharmaceuticals' product development activities and clinical trials, including planned Phase 3 clinical trial for ARX-04; the market potential for its product candidates; and other risks detailed in the "Risk Factors" and elsewhere in AcelRx's U.S. Securities and Exchange Commission filings and reports, including its Annual Report on Form 10-K filed with the SEC on March 17, 2014. AcelRx undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.  AcelRx logo.  Logo - http://photos.prnewswire.com/prnh/20130226/MM67303LOGO  SOURCE AcelRx Pharmaceuticals, Inc.  Website: http://www.acelrx.com Contact: Tim Morris, Chief Financial Officer, 650.216.3511, tmorris@acelrx.com; or Brian Korb, The Trout Group LLC, 646.378.2923, bkorb@troutgroup.com  
Press spacebar to pause and continue. Press esc to stop.